Learn More About Power

Why We Started Power

We started Power when my dad was diagnosed with multiple myeloma, and I struggled to help him access the latest immunotherapy. Hopefully Power makes it simpler for you to explore promising new treatments, during what is probably a difficult time.

Bask
Bask GillCEO at Power
Learn More About Trials
How Do Clinical Trials Work?Are Clinical Trials Safe?What Can I Expect During a Clinical Trial?
Unbiased ResultsWe believe in providing patients with all the options.
Your Data Stays Your DataWe only share your information with the clinical trials you're trying to access.
Verified Trials OnlyAll of our trials are run by licensed doctors, researchers, and healthcare companies.
1045 Sansome St, Suite 321, San Francisco, CA
hello@withpower.com(415) 900-4227
About UsClinical Trials by ConditionAll Clinical TrialsWork With Us
1
Directories
Conditions
Cities
States
Popular Categories
Depression & Anxiety
Neurology
Psychiatry
Pain
Metabolism
Treatments
Locations
Florida
New Jersey
North Carolina
Texas
Ohio
California
Pennsylvania
Kentucky
New York
Indiana
Psychology Related
Depression
Schizophrenia
Anxiety
PTSD
ADHD
Autism
Bipolar Disorder
Addiction
OCD
Eating Disorder
Treatments
Psilocybin
IVF
Dental Implant
Weight Loss
Smoking
Platelet-Rich Plasma
Testosterone
Saxenda
Melatonin
Entresto
Cities
Saint Louis
Columbus
Portland
Ann Arbor
Aurora
Salt Lake City
Rochester
Birmingham
Detroit
New Haven
Terms of Service·Privacy Policy·Cookies
Cookies & Data Use Policy

At Power, we believe in using data responsibly to help you find the right clinical trials — without compromising your privacy. This page explains how we use cookies and personal data across www.withpower.com.

Before You Create a Profile

When you browse Power's website, you're opting in to our use of cookies. Cookies are used to improve your experience and help us understand how the site is used so that we can make improvements for you in the future. Specifically, we use cookies to:

Personalize Your Experience

We use cookies to customize your visit based on basic information like your general location (determined by your IP address). This allows us to:

  • Show you clinical trials that are geographically relevant to you
  • Tailor search results to match the conditions or keywords you've explored before
  • Pre-fill certain fields or remember your previous searches, so you don't have to repeat them

Save Your Preferences

We remember what you interact with during your visit — for example:

  • The conditions you search for
  • Whether you prefer certain types of studies (e.g., paid trials, trials for a specific age group)
  • Your sorting or filtering preferences when browsing trials

This helps us make your experience more efficient and personalized the next time you visit.

Understand How the Site Is Used

Cookies help us collect anonymous usage data so we can make Power better. We use these insights to:

  • Monitor how users move through the site — for example, which pages get the most traffic and where users tend to exit
  • Track how long visitors stay on each page and whether they find what they’re looking for
  • Identify points of friction or confusion so we can improve usability
  • Test design changes (like different page layouts or buttons) and measure which version performs better
  • Detect and fix bugs or slow-loading pages to maintain site reliability

These analytics are aggregated and do not include personal identifiers. We use tools like Google Analytics to process this data, but we don't use it to target ads or sell your information.

We do not:

  • Sell or share your personal data with advertisers
  • Use your behavior on our site to target you with third-party ads

All cookie use is designed to support your experience on Power — never to track you across the internet or monetize your information.

After You Create a Profile

When you sign up for a Power account, you agree to our Privacy Policy and Terms of Service. Creating a profile allows us to better serve you by tailoring the platform to your specific needs.

Once you create a profile:

  • We may collect additional information about your health and clinical interests to help us match you to the most relevant studies.
  • We continue to use cookies to remember your session, keep you logged in, and personalize your dashboard.
  • You have full control — you can delete your profile at any time, and we'll remove your personal data in accordance with our privacy practices.

We use your data solely to fulfill our mission: helping you find clinical trials that could be a fit — not for advertising or resale.

·Security
Condition
Suggested Conditions
  • Anxiety
  • Depression
  • Alzheimer's Disease
  • Weight Loss
  • Heart Disease
  • Cancer
  • Asthma
Location

    Arthritis

    Current Location

    Search
    Arthritis
    Show Map
    Map View
    Your Location
    Search Clinical Trials
    Conditions
    Suggestions
    • Anxiety
    • Depression
    • Alzheimer's Disease
    • Weight Loss
    • Heart Disease
    • Cancer
    • Asthma
    Locations
    Suggestions
      Treatment Type
      Suggestions
      • Cognitive Behavioral Therapy
      • Medication Management
      • Group Therapy
      • Psychotherapy
      • Mindfulness-Based Therapy
      • Exposure Therapy

      Trial Phase

      Trial Status

      Paid Participation

      Filters

      0

      Suggestions
      • Cognitive Behavioral Therapy
      • Medication Management
      • Group Therapy
      • Psychotherapy
      • Mindfulness-Based Therapy
      • Exposure Therapy

      Paid Participation

      Trial Status

      Trial Phase

      Clear All
      Why We Started Power

      We started Power when my dad was diagnosed with multiple myeloma, and I struggled to help him access the latest immunotherapy. Hopefully Power makes it simpler for you to explore promising new treatments, during what is probably a difficult time.

      Bask
      Bask GillCEO at Power
      Learn More About Trials
      How Do Clinical Trials Work?Are Clinical Trials Safe?What Can I Expect During a Clinical Trial?

      98 Arthritis Trials Near You

      Power is an online platform that helps thousands of Arthritis patients discover FDA-reviewed trials every day. Every trial we feature meets safety and ethical standards, giving patients an easy way to discover promising new treatments in the research stage.

      Learn More About Power
      No Placebo
      Highly Paid
      Stay on Current Meds
      Pivotal Trials (Near Approval)
      Breakthrough Medication

      Baricitinib vs TNF Inhibitors for Rheumatoid Arthritis

      Columbus, Ohio
      This post-marketing study is designed to compare the safety of baricitinib versus tumor necrosis factor (TNF) inhibitors with respect to venous thromboembolic events (VTEs) when given to participants with rheumatoid arthritis.
      No Placebo Group
      Prior Safety Data

      Trial Details

      Trial Status:Active Not Recruiting
      Trial Phase:Phase 4

      Key Eligibility Criteria

      Disqualifiers:Cancer, Serious Infection, Tuberculosis, Others
      Must Be Taking:DMARDs

      2600 Participants Needed

      ZILRETTA for Shoulder Osteoarthritis

      Columbus, Ohio
      Primary Objective: To assess the efficacy of ZILRETTA on pain following an intra-articular (IA) injection in subjects with glenohumeral osteoarthritis (OA) relative to normal saline placebo Secondary Objective: * To assess the efficacy of ZILRETTA on pain following an IA injection in subjects with glenohumeral OA relative to triamcinolone acetonide injectable suspension, and normal saline placebo * To assess the safety of ZILRETTA in subjects with glenohumeral OA relative to normal saline placebo
      Pivotal Trial (Near Approval)

      Trial Details

      Trial Status:Recruiting
      Trial Phase:Phase 3
      Age:50 - 80

      Key Eligibility Criteria

      Disqualifiers:Symptomatic Arthritis, Rotator Cuff Pathology, Chronic Shoulder Pain, Others
      Must Not Be Taking:Opioids, Analgesics, THC/CBD, SSRIs/SNRIs

      150 Participants Needed

      CC-97540 for Severe Refractory Lupus

      Columbus, Ohio
      This trial is testing a new drug called CC-97540. It aims to help people with severe autoimmune diseases that don't get better with regular treatments. Researchers want to see if the drug is safe, how it moves through the body, and if it can improve patients' health.
      No Placebo Group

      Trial Details

      Trial Status:Recruiting
      Trial Phase:Phase 1

      Key Eligibility Criteria

      Disqualifiers:Drug-induced SLE, Multiple Sclerosis, Psoriasis, Others

      270 Participants Needed

      TNFi Therapy Strategies for Juvenile Spondyloarthritis

      Columbus, Ohio
      This randomized pragmatic trial will generate knowledge about strategies used to de-escalate tumor necrosis factor inhibitor (TNFi) therapy in patients with juvenile spondyloarthritis with sustained inactive disease and are treated at one of the 29 participating pediatric healthcare systems. This open label study will be conducted in the setting of routine clinical care and will compare the risk and timing of flare (Aim 1) and patients' lived experiences (Aim 2) across three arms.
      No Placebo Group

      Trial Details

      Trial Status:Active Not Recruiting
      Trial Phase:Unphased
      Age:8 - 21

      Key Eligibility Criteria

      Disqualifiers:Inflammatory Bowel Disease, Uncontrolled Uveitis, Psoriasis, Others
      Must Be Taking:TNFi Therapies

      164 Participants Needed

      TTAX03 Injection for Knee Osteoarthritis

      Columbus, Ohio
      This trial tests if a single injection of TTAX03 in saltwater can improve knee conditions better than just saltwater. It targets patients needing knee injections and checks their response over a few months.

      Trial Details

      Trial Status:Active Not Recruiting
      Age:35 - 85

      Key Eligibility Criteria

      Disqualifiers:Not Listed

      90 Participants Needed

      Abatacept Injection for Juvenile Idiopathic Arthritis

      Columbus, Ohio
      This is a research study to test whether a once-weekly injection of abatacept will prevent the progression of Juvenile Idiopathic Arthritis (JIA) to a more severe form. To evaluate the effectiveness of a 24-week course of treatment with abatacept plus usual care versus usual care to prevent polyarthritis (≥5 joints), uveitis, or treatment with other systemic medication within 18 months of randomization in children with recent-onset limited JIA.
      No Placebo Group
      Pivotal Trial (Near Approval)

      Trial Details

      Trial Status:Active Not Recruiting
      Age:2 - 16

      Key Eligibility Criteria

      Disqualifiers:Not Listed

      121 Participants Needed

      Curcumin for Joint Pain in Breast Cancer Survivors

      Columbus, Ohio
      This trial studies whether a special form of curcumin can reduce joint pain in breast cancer survivors who have pain from their cancer treatment. Curcumin, found in turmeric, is known for its anti-inflammatory effects. The trial aims to see if this natural substance can help these patients feel better. Curcumin, derived from turmeric, has been used in traditional medicine for centuries and has shown potential anticancer and anti-inflammatory properties in various studies.

      Trial Details

      Trial Status:Active Not Recruiting
      Trial Phase:Unphased
      Sex:Female

      Key Eligibility Criteria

      Disqualifiers:Anemia, Autoimmune, Cardiac, Infections, Others
      Must Be Taking:Aromatase Inhibitors

      42 Participants Needed

      Intermittent Fasting Diet for Psoriasis and Psoriatic Arthritis

      Columbus, Ohio
      Our study aims to determine whether intermittent fasting (IMF) is a valid method to improve psoriasis and psoriatic arthritis (PsA) disease severity and quality of life. Patients within OSU Dermatology with psoriasis and/or psoriatic arthritis will be enrolled in a dietary intervention for a 24-week period. A prospective, single-blind parallel group randomized control trial will include an IMF dietary intervention group and a standard routine diet group for a duration of 24 weeks. After the initial 12 weeks of the dietary intervention, patients will be followed for an additional 12 weeks to assess changes in their disease state and quality of life after returning to their initial dietary routines. In total, the study will be 24 weeks. Baseline assessment will consist of standard psoriasis and PsA clinical parameters; evaluation will be performed by a blinded physician. These parameters will be reassessed every 4 weeks via video visit for the three month duration of the study, and then again at the 24-week conclusion of the study. In addition, each visit will assess patient-reported outcomes using dermatology-specific quality of life indices. Biometric measurements of weight, height, BMI, and waist-to-hip ratio will be recorded at baseline and all subsequent visits. Dietary adherence will be assessed by virtual check-in visits, and dietary guidance will be provided and reviewed at each visit by the research coordinator. A physician or the research coordinator will be available for questions between times of data collection. The primary outcome measure will be feasibility of a larger study, which will be determined at the initial 12-week timepoint. This data is vital to determine effect size and dropout frequency for future studies. Secondary outcomes will include changes in clinical indices, biometric measurements, and quality of life indices at 12 weeks after randomization and at the end of the 24-week study. Achievement of a 5% weight reduction at 12 weeks, and a 10-15% weight reduction at 24 weeks will be additional secondary endpoints. Data for each patient will be stored in a password-protected and encrypted REDCAP database on a secure OSU server.
      No Placebo Group

      Trial Details

      Trial Status:Active Not Recruiting
      Trial Phase:Unphased

      Key Eligibility Criteria

      Disqualifiers:Pregnancy, Insulin-dependent Diabetes, Severe Heart Disease, Others
      Must Not Be Taking:Weight Loss Drugs

      60 Participants Needed

      Bone Marrow Collection for Hip Arthritis

      Columbus, Ohio
      Six patients with diagnosed bone loss of the hip who have consented to minimally invasive repair will be approached to participate in the study. Participants will have the liquid portion of bone marrow collected using the Zimmer Biomet Biocue system, which is the standard system used by physicians at The Ohio State University, and the novel Marrow Cellutions system™. Bone marrow liquid will be collected from the surgical hip using the Zimmer Biomet Biocue system, and the Marrow Cellutions system™ will be used to collect bone marrow liquid from the non-surgical hip. Following collection, the bone marrow liquid will be processed using the respective systems to concentrate the cells and molecules found in the bone marrow liquid. As part of the standard of care for this arthroscopic procedure, concentrated bone marrow liquid processed using the Zimmer Biomet Biocue system will be delivered to the surgical site as an adjunct to promote healing. Concentrated bone marrow liquid prepared with the Zimmer Biomet Biocue system is given as part of the standard of care for patients undergoing minimally invasive treatment for bone loss of the hip; therefore, the target population for this study are individuals between the ages of 18-50 years with confirmed bone loss of the hip who have consented to minimally invasive repair. In addition to the concentrated bone marrow liquid prepared using the Zimmer Biomet Biocue system, patients will also have bone marrow liquid collected from the non-surgical hip using the Marrow Cellutions™ system. Only concentrated bone marrow liquid produced with the Zimmer Biomet Biocue system will be given to the patient. All concentrated bone marrow liquid produced with the Marrow Cellutions™ system will be sent to the laboratory for analysis. Additionally, white blood cells will be concentrated into an autologous protein solution (APS) using the Zimmer Biomet Plasmax system from blood collected using a routine blood draw. All protein solution produced will be sent to the laboratory for analysis. No protein solution will be given to the patient. As the bone marrow liquid collection using the Marrow Cellutions™ system and the blood draw to produce protein solution using the Zimmer Biomet Plasmax system are being performed for research,
      No Placebo Group

      Trial Details

      Trial Status:Recruiting
      Trial Phase:Unphased
      Age:18 - 50

      Key Eligibility Criteria

      Disqualifiers:Hematologic Issues, Leukemia, Diabetes, Others

      6 Participants Needed

      Knee Replacement for Osteoarthritis

      Columbus, Ohio
      The primary objective of this study is to obtain implant survivorship and clinical outcomes data for commercially available Persona fixed bearing knee implants used in total knee arthroplasty. The assessment will include implant survivorship and clinical performance.
      No Placebo Group

      Trial Details

      Trial Status:Active Not Recruiting
      Trial Phase:Unphased

      Key Eligibility Criteria

      Disqualifiers:Infection, Osteoporosis, Neuromuscular Disease, Others

      737 Participants Needed

      Emapalumab for MAS in Still's Disease or Lupus

      Columbus, Ohio
      This trial is testing emapalumab, a medication that helps control an overactive immune system, in children and adults with certain immune conditions who haven't responded to high-dose steroids. The goal is to see if it is safe and effective in reducing excessive inflammation. Emapalumab is a monoclonal antibody that targets interferon-γ and was first approved for treating primary hemophagocytic lymphohistiocytosis (HLH) in patients with refractory, recurrent, or progressive disease.
      No Placebo Group
      Pivotal Trial (Near Approval)

      Trial Details

      Trial Status:Active Not Recruiting
      Trial Phase:Phase 3
      Age:6 - 80

      Key Eligibility Criteria

      Disqualifiers:Primary HLH, Malignancy, Active Infections, Others
      Must Be Taking:Glucocorticoids

      41 Participants Needed

      Ketogenic Diet for Rheumatoid Arthritis

      Columbus, Ohio
      This is a 6-week ketogenic diet (KD) intervention where participants with rheumatoid arthritis (RA) will follow a KD plan, supervised and monitored by a dietician. Participants will be provided extensive educational and ongoing support on the KD, including personalized coaching with the ability to text a dietitian at any time and expect a response within 12 hours. Diet adherence and progress will be assessed daily using at-home blood ketone/glucose monitors, along with diet records. Participants will fill out health related questionnaires and undergo assessments of body composition, RA disease activity. This study also includes blood draws and fat biopsy of the abdominal region.
      No Placebo Group

      Trial Details

      Trial Status:Enrolling By Invitation
      Trial Phase:Unphased
      Age:18 - 65

      Key Eligibility Criteria

      Disqualifiers:Chronic Inflammatory, Autoimmune, Malignancy, Others
      Must Be Taking:Dmards, Biological Agents

      6 Participants Needed

      Hip Implant for Hip Replacement

      Columbus, Ohio
      The main objectives of this study are to confirm the long-term safety, performance, and clinical benefits of the G7 Freedom Constrained Vivacit-E Acetabular Liners in primary and revision total hip arthroplasty.
      No Placebo Group

      Trial Details

      Trial Status:Enrolling By Invitation
      Trial Phase:Unphased

      Key Eligibility Criteria

      Disqualifiers:Infection, Osteoporosis, Metabolic Disorders, Others

      202 Participants Needed

      Nivolumab for Cancer

      Columbus, Ohio
      This phase Ib trial studies the side effects of nivolumab and to see how well it works in treating patients with autoimmune disorders and cancer that has spread to other places in the body or cannot removed by surgery. Immunotherapy with monoclonal antibodies, such as nivolumab, may help the body's immune system attack the cancer, and may interfere with the ability of tumor cells to grow and spread.
      No Placebo Group
      Prior Safety Data

      Trial Details

      Trial Status:Recruiting
      Trial Phase:Phase 1

      Key Eligibility Criteria

      Disqualifiers:Chemotherapy, Radiotherapy, Allogeneic Transplant, Others
      Must Not Be Taking:Anticancer Investigational Agents

      300 Participants Needed

      BMS-986278 for Pulmonary Fibrosis

      Columbus, Ohio
      The purpose of this study is to evaluate the efficacy, safety, and tolerability of BMS-986278 in Participants with Progressive Pulmonary Fibrosis.
      Pivotal Trial (Near Approval)

      Trial Details

      Trial Status:Recruiting
      Trial Phase:Phase 3
      Age:21+

      Key Eligibility Criteria

      Disqualifiers:Idiopathic Pulmonary Fibrosis, Stroke, Heart Failure, Current Malignancy, Others
      Must Not Be Taking:Systemic Corticosteroids

      1092 Participants Needed

      Amniotic Suspension Allograft for Knee Osteoarthritis

      Columbus, Ohio
      This trial is testing if injecting ASA into the knee can help people with knee osteoarthritis feel better. The study will check pain levels, knee function, and safety over several months. ASA (Amniotic Suspension Allograft) has been shown to be an effective treatment for knee osteoarthritis in previous studies.
      Pivotal Trial (Near Approval)

      Trial Details

      Trial Status:Active Not Recruiting
      Trial Phase:Phase 3
      Age:19+
      Sex:Male

      Key Eligibility Criteria

      Disqualifiers:Knee Surgery, Infection, Substance Use, Others
      Must Not Be Taking:Anticoagulants, Immunosuppressives, Steroids

      474 Participants Needed

      Baricitinib for Rheumatoid Arthritis

      Marion, Ohio
      This trial compares the safety of two treatments for rheumatoid arthritis, focusing on the risk of blood clots. One treatment is baricitinib, an oral medication used for moderate to severe cases.
      No Placebo Group
      Prior Safety Data

      Trial Details

      Trial Status:Recruiting
      Trial Phase:Phase 4

      Key Eligibility Criteria

      Disqualifiers:Cancer, Active Tuberculosis, Serious Infection, Others
      Must Be Taking:DMARDs

      1300 Participants Needed

      Bimekizumab for Psoriatic Arthritis

      Vandalia, Ohio
      The purpose of the study is to compare the efficacy of bimekizumab versus risankizumab after 16 weeks of treatment in study participants with active psoriatic arthritis (PsA).
      Pivotal Trial (Near Approval)

      Trial Details

      Trial Status:Active Not Recruiting
      Trial Phase:Phase 3

      Key Eligibility Criteria

      Disqualifiers:Active Infection, Tuberculosis, Rheumatoid Arthritis, Others
      Must Be Taking:CsDMARDs

      684 Participants Needed

      Upadacitinib for Rheumatoid Arthritis

      Dayton, Ohio
      The purpose of this study was to assess efficacy, including inhibition of radiographic progression, and safety with upadacitinib versus placebo and versus an active comparator, adalimumab, in adults with with moderately to severely active rheumatoid arthritis (RA) who are on a stable background of methotrexate (MTX and who have an inadequate response to MTX.
      Pivotal Trial (Near Approval)

      Trial Details

      Trial Status:Active Not Recruiting
      Trial Phase:Phase 3

      Key Eligibility Criteria

      Disqualifiers:Adalimumab, Inadequate BDMARD Response, Others
      Must Be Taking:Methotrexate

      1629 Participants Needed

      Aptis PRUJ Prosthesis for Arthritis

      Dayton, Ohio
      A Prospective, Multi-Center, Single-Arm Clinical Trial of the safety and effectiveness of the Aptis PRUJ prosthesis for the treatment of patients with proximal radial ulna joint disorders
      No Placebo Group

      Trial Details

      Trial Status:Recruiting
      Trial Phase:Unphased

      Key Eligibility Criteria

      Disqualifiers:Severe Arthritis, Infection, High BMI, Others
      Must Not Be Taking:Corticosteroids, NSAIDs

      84 Participants Needed

      Why Other Patients Applied

      "I've been 17+ years in pain with bilateral osteoarthritis. PRP and HA injections have not helped. Physical therapy has helped only to a certain degree. I'm looking for new treatment options before considering replacement. "

      RH
      Arthritis PatientAge: 39

      "I have been struggling with severe knee pain since my service in the military. I am only 52! I miss doing the things I used to do."

      NA
      Arthritis PatientAge: 55

      "I am an active athlete who is not ready or willing to stop my activities because of knee pain at 42. I have tried cortisone shots and found they only temporary mask the issue, or even cause more problems later. That's why I started researching medical studies."

      GM
      Arthritis PatientAge: 44

      "I’ve tried several meds without too much relief. Injections only work on my right knee but not much on the left knee. My pain is nearly unbearable at this point. Hoping to learn about what promising drugs exist in trials."

      YV
      Arthritis PatientAge: 61

      "My orthopedist recommended a half replacement of my right knee. I have had both hips replaced. Currently have arthritis in knee, shoulder, and thumb. I want to avoid surgery, and I'm open-minded about trying a trial before using surgery as a last resort."

      HZ
      Arthritis PatientAge: 78
      Match to a Arthritis Trial

      Guselkumab for Psoriatic Arthritis

      Dayton, Ohio
      The purpose of this study is to evaluate the efficacy of guselkumab treatment in participants with active psoriatic arthritis (PsA) by assessing the reduction in signs and symptoms of PsA.
      Pivotal Trial (Near Approval)

      Trial Details

      Trial Status:Active Not Recruiting
      Trial Phase:Phase 3

      Key Eligibility Criteria

      Disqualifiers:Rheumatoid Arthritis, Lupus, Others
      Must Not Be Taking:Biologics, JAK Inhibitors

      1054 Participants Needed

      Bimekizumab for Psoriatic Arthritis

      Vandalia, Ohio
      This trial is testing the safety and effectiveness of bimekizumab, a medication given as an injection under the skin. It is aimed at adults who have psoriatic arthritis, a condition that causes joint pain and swelling. Bimekizumab works by blocking proteins that cause inflammation, helping to reduce pain and swelling.
      No Placebo Group
      Pivotal Trial (Near Approval)

      Trial Details

      Trial Status:Active Not Recruiting
      Trial Phase:Phase 3

      Key Eligibility Criteria

      Disqualifiers:Pregnancy, Serious Infections, Others

      1131 Participants Needed

      AR882 for Gout

      Dayton, Ohio
      This study will assess the serum uric acid lowering effect and safety of AR882 in gout patients at two doses compared to placebo over 12 months
      Pivotal Trial (Near Approval)

      Trial Details

      Trial Status:Active Not Recruiting
      Trial Phase:Phase 3

      Key Eligibility Criteria

      Disqualifiers:Malignancy, Pregnant, Kidney Stones, Others

      750 Participants Needed

      Risankizumab for Psoriatic Arthritis

      Springboro, Ohio
      The purpose of this study is to compare the safety and efficacy of risankizumab versus placebo in participants with moderately to severely active psoriatic arthritis (PsA).
      Pivotal Trial (Near Approval)

      Trial Details

      Trial Status:Active Not Recruiting
      Trial Phase:Phase 3

      Key Eligibility Criteria

      Disqualifiers:Hypersensitivity To Risankizumab, Others
      Must Not Be Taking:Biologic Agents

      964 Participants Needed

      Guselkumab vs Golimumab for Psoriatic Arthritis

      Wheelersburg, Ohio
      The trial is an open-label randomized study that will examine whether switching to a selective IL23 inhibitor (guselkumab) is more effective than switching to a second TNFi (golimumab) among patients with PsA who have an inadequate response to a TNFi.
      No Placebo Group
      Pivotal Trial (Near Approval)

      Trial Details

      Trial Status:Recruiting
      Trial Phase:Phase 3

      Key Eligibility Criteria

      Disqualifiers:Pregnancy, Heart Failure, Others
      Must Be Taking:TNFi, OSM/csDMARDs

      63 Participants Needed

      Non-TNFi Biologics vs Targeted Synthetic DMARDs for Rheumatoid Arthritis

      Wheelersburg, Ohio
      This trial is testing advanced medications for RA patients who haven't responded to standard treatments. It compares biologic drugs that target immune proteins and synthetic drugs that block harmful molecules in immune cells. The goal is to see which treatment improves patients' quality of life and daily functioning better. Biologic therapies have notably improved the treatment of RA, making disease remission a realistic goal.
      No Placebo Group
      Pivotal Trial (Near Approval)

      Trial Details

      Trial Status:Recruiting
      Trial Phase:Phase 3

      Key Eligibility Criteria

      Disqualifiers:HIV, Heart Failure, Hepatitis, Others
      Must Be Taking:TNFi-biologic

      924 Participants Needed

      AR882 for Gout

      Mason, Ohio
      This study will assess the serum uric acid lowering effect and safety of AR882 in gout patients at two doses compared to placebo over 12 months
      Pivotal Trial (Near Approval)

      Trial Details

      Trial Status:Active Not Recruiting
      Trial Phase:Phase 3

      Key Eligibility Criteria

      Disqualifiers:Malignancy, Pregnant, Kidney Stones, Others

      750 Participants Needed

      Tildrakizumab SC Injection for Psoriatic Arthritis

      Cincinnati, Ohio
      An open label phase 3 study
      No Placebo Group
      Pivotal Trial (Near Approval)

      Trial Details

      Trial Status:Enrolling By Invitation
      Trial Phase:Phase 3

      Key Eligibility Criteria

      Disqualifiers:Pregnancy, Breastfeeding, Others

      650 Participants Needed

      Deucravacitinib for Psoriatic Arthritis

      Cincinnati, Ohio
      The purpose of this study is to evaluate the drug levels, efficacy, and safety of Deucravacitinib (BMS-986165) in pediatric participants with juvenile psoriatic arthritis.
      Pivotal Trial (Near Approval)

      Trial Details

      Trial Status:Recruiting
      Trial Phase:Phase 3
      Age:5 - 17

      Key Eligibility Criteria

      Disqualifiers:Other JIA, Uveitis, Others

      60 Participants Needed

      Secukinumab for Giant Cell Arteritis and Polymyalgia Rheumatica

      Cincinnati, Ohio
      This study will examine how intravenous (i.v.) Secukinumab will be processed in the body (pharmacokinetics \[PK\]) and whether it will be safe and tolerable after multiple doses of i.v. Secukinumab infusion in adult patients with giant cell arteritis (GCA) or polymyalgia rheumatica (PMR).
      No Placebo Group

      Trial Details

      Trial Status:Active Not Recruiting
      Trial Phase:Phase 1
      Age:50 - 100

      Key Eligibility Criteria

      Disqualifiers:Not Listed

      65 Participants Needed

      1234

      Know someone looking for new options?
      Spread the word

      Why We Started Power

      We started Power when my dad was diagnosed with multiple myeloma, and I struggled to help him access the latest immunotherapy. Hopefully Power makes it simpler for you to explore promising new treatments, during what is probably a difficult time.

      Bask
      Bask GillCEO at Power
      Learn More About Trials
      How Do Clinical Trials Work?Are Clinical Trials Safe?What Can I Expect During a Clinical Trial?
      Match to a Trial
      Match to a Trial

      Popular Searches

      By Condition

      Depression Clinical Trials

      Anxiety Clinical Trials

      Schizophrenia Clinical Trials

      ADHD Clinical Trials

      Bipolar Disorder Clinical Trials

      Multiple Sclerosis Clinical Trials

      Autism Clinical Trials

      Treatment Resistant Depression Clinical Trials

      Borderline Personality Disorder Clinical Trials

      Social Anxiety Disorder Clinical Trials

      Parkinson's Disease Clinical Trials

      Alzheimer's Disease Clinical Trials

      By Location

      Clinical Trials in California

      Clinical Trials in Florida

      Clinical Trials in Texas

      Clinical Trials in New York

      Clinical Trials in Ohio

      Clinical Trials in Illinois

      Clinical Trials in Pennsylvania

      Clinical Trials in Michigan

      Clinical Trials in North Carolina

      Clinical Trials in Massachusetts

      Clinical Trials in Missouri

      Clinical Trials in Minnesota

      Other People Viewed

      By Subject

      Top Psoriatic Arthritis Clinical Trials

      Top Rheumatoid Arthritis Clinical Trials

      Top Juvenile Idiopathic Arthritis Clinical Trials

      38 Arthritis Trials near Raleigh, NC

      60 Arthritis Trials near Houston, TX

      17 Arthritis Trials near Columbus, OH

      48 Arthritis Trials near Phoenix, AZ

      14 Arthritis Trials near Sacramento, CA

      Top Shingles Clinical Trials

      Top Prostatitis Clinical Trials

      Top Adenovirus Clinical Trials

      Top Osteopenia Clinical Trials

      By Trial

      Diet Intervention for Juvenile Arthritis

      Upadacitinib for Rheumatoid Arthritis

      Multidisciplinary Care for Rheumatoid Arthritis

      Anti-Inflammatory Diet for Rheumatoid Arthritis

      Mindfulness Program for Children with Juvenile Arthritis

      Adipose Allograft for Hand Arthritis

      Butyrate for Rheumatoid Arthritis

      OACareTools+ for Osteoarthritis

      Subscapularis Repair in Shoulder Replacement for Shoulder Arthritis

      Steroids for Post-Tonsillectomy Pain

      Bonipar for Musculoskeletal Pain

      Selective Dorsal Rhizotomy for Cerebral Palsy

      Related Searches

      SAGE-718 for Huntington's Disease

      Deutetrabenazine for Tardive Dyskinesia

      Top Clinical Trials near Dubois, PA

      Mezigdomide Combo vs. Pomalidomide Combo for Multiple Myeloma

      Gene Therapy for Radiation-Induced Dry Mouth

      Lyme Disease Vaccine for Healthy Children

      HS-20118 for Psoriasis

      Transcranial Magnetic Stimulation for Misophonia

      Healthbot Support for Medication Adherence

      Manipulation & Dry Needling vs. Mobilization & Massage for Tension Headaches

      GSK5764227 for Small Cell Lung Cancer

      Game-Based Intervention for HPV Vaccination

      Frequently Asked Questions

      How much do Arthritis clinical trials pay?

      Each trial will compensate patients a different amount, but $50-100 for each visit is a fairly common range for Phase 2–4 trials (Phase 1 trials often pay substantially more). Further, most trials will cover the costs of a travel to-and-from the clinic.

      How do Arthritis clinical trials work?

      After a researcher reviews your profile, they may choose to invite you in to a screening appointment, where they'll determine if you meet 100% of the eligibility requirements. If you do, you'll be sorted into one of the treatment groups, and receive your study drug. For some trials, there is a chance you'll receive a placebo. Across Arthritis trials 30% of clinical trials have a placebo. Typically, you'll be required to check-in with the clinic every month or so. The average trial length for Arthritis is 12 months.

      How do I participate in a study as a "healthy volunteer"?

      Not all studies recruit healthy volunteers: usually, Phase 1 studies do. Participating as a healthy volunteer means you will go to a research facility several times over a few days or weeks to receive a dose of either the test treatment or a "placebo," which is a harmless substance that helps researchers compare results. You will have routine tests during these visits, and you'll be compensated for your time and travel, with the number of appointments and details varying by study.

      What does the "phase" of a clinical trial mean?

      The phase of a trial reveals what stage the drug is in to get approval for a specific condition. Phase 1 trials are the trials to collect safety data in humans. Phase 2 trials are those where the drug has some data showing safety in humans, but where further human data is needed on drug effectiveness. Phase 3 trials are in the final step before approval. The drug already has data showing both safety and effectiveness. As a general rule, Phase 3 trials are more promising than Phase 2, and Phase 2 trials are more promising than phase 1.

      Do I need to be insured to participate in a Arthritis medical study?

      Clinical trials are almost always free to participants, and so do not require insurance. The only exception here are trials focused on cancer, because only a small part of the typical treatment plan is actually experimental. For these cancer trials, participants typically need insurance to cover all the non-experimental components.

      What are the newest Arthritis clinical trials?

      Most recently, we added MAS825 for Still's Disease, Methylprednisolone for Knee Arthritis and Secukinumab for Psoriatic Arthritis to the Power online platform.